Rapacuronium

Rapacuronium bromide was introduced in the US as a parenterally administered adjunct to general anesthesia during surgical procedures. It is a new steroidal derivative belonging to the same class as vecuronium bromide. This 2,16-bispiperidinylandrostane derivative can be synthesized in 3 steps from the 3-hydroxy-androstan-17-one analog and finally quaternized with allyl bromide. Rapacuronium bromide is a nondepolarizing neuromuscular blocking drug with a rapid onset and a short duration of action. With a relatively low potency (ED₉₀ = 1.15 mg/kg), Rapacuronium is expected to be substituted for the polarizing succinylcholine with very short duration of action.

Akzo Nobel (Netherlands)

Rapacuronium Bromide is an aminosteroidal nondepolarizing neuromuscular blocking agent and was used as a anesthesia.

Raplon